Table 4.
SVR12 valuesa for clinical-trial regimens with and without RBV in patients who were (i) cirrhotic or non-cirrhoticb, (ii) treatment-experienced or -naïve, or (iii) HIV-positive or -negative
| Regimen | SVR12% [95% CI] | ||||||
|---|---|---|---|---|---|---|---|
| Cirrhotic | Non-cirrhotic | Treatment-experienced | Treatment-naïve | HIV-positive | HIV-negative | ||
| DCV + SOF containing regimens | |||||||
| DCV + SOF | +RBV | 87.3 [74.1, 96.9] n = 42 |
95.5 [76.0, 100.0] n = 16 |
NR | 100.0 [68.3, 100.0] n = 5 |
NR | 100.0 [68.3, 100.0] n = 5 |
| −RBV | 62.5 [44.9, 78.6] n = 32 |
97.4 [93.2, 99.8] n = 136 |
90.8 [79.6, 98.4] n = 55 |
91.7 [87.9, 94.9] n = 328 |
92.3 [69.9, 100.0] n = 13 |
89.6 [84.1, 94.2] n = 165 |
|
| GZR containing regimens | |||||||
| GZR + EBR + MK-3682 | +RBV | NR | NR | NR | NR | NR | NR |
| −RBV | NR | 88.4 [76.8, 96.5] n = 43 |
NR | 88.4 [76.8, 96.5] n = 43 |
NR | 88.4 [76.8, 96.5] n = 43 |
|
| GZR + RZR + MK-3682 | +RBV | NR | NR | NR | NR | NR | NR |
| −RBV | NR | 93.0 [83.1, 99.1] n = 43 |
NR | 93.0 [83.1, 99.1] n = 43 |
NR | 93.0 [83.1, 99.1] n = 43 |
|
| GZR + EBR + SOF | +RBV | NR | NR | NR | NR | NR | NR |
| −RBV | 90.9 [65.0, 100.0] n = 11 |
96.6 [85.8, 100.0] n = 29 |
NR | 95.0 [85.5, 99.9] n = 40 |
NR | 95.0 [85.5, 99.9] n = 40 |
|
| LDV containing regimens | |||||||
| LDV + SOF | +RBV | 79.1 [68.3, 88.3] n = 67 |
93.2 [87.0, 97.7] n = 98 |
82.0 [70.0, 91.6] n = 50 |
91.3 [87.3, 94.7] n = 246 |
NR | 88.2 [79.8, 94.6] n = 76 |
| −RBV | NR | NR | NR | 64.0 [44.0, 81.9] n = 25 |
NR | 64.0 [44.0, 81.9] n = 25 |
|
| OBV containing regimens | |||||||
| OBV + PTV/r | +RBV | NR | 50.0 [18.9, 81.1] n = 10 |
NR | 50.0 [18.9, 81.1] n = 10 |
NR | 50.0 [18.9, 81.1] n = 10 |
| −RBV | NR | 9.1 [0.0, 35.0] n = 11 |
NR | 9.1 [0.0, 35.0] n = 11 |
NR | 9.1 [0.0, 35.0] n = 11 |
|
| OBV + PTV/r + SOF | +RBV | NR | 90.9 [65.0, 100.0] n = 11 |
NR | NR | NR | NR |
| −RBV | NR | 100.0 [81.7, 100.0] n = 9 |
NR | NR | NR | NR | |
| PIB containing regimens | |||||||
| PIB + GLE | +RBV | 100.0 [93.0, 100.0] n = 24 |
NR | NR | 100.0 [93.0, 100.0] n = 24 |
NR | 100.0 [93.0, 100.0] n = 24 |
| −RBV | 100.0 [93.0, 100.0] n = 24 |
94.6 [88.5, 98.7] n = 89 |
66.7 [5.9, 100.0] n = 3 |
98.0 [92.9, 100.0] n = 80 |
NR | 97.1 [91.7, 100.0] n = 83 |
|
| PIB + PTV/r | +RBV | NR | 90.0 [61.9, 100.0] n = 10 |
NR | 90.0 [61.9, 100.0] n = 10 |
NR | 90.0 [61.9, 100.0] n = 10 |
| −RBV | NR | NR | NR | NR | NR | NR | |
| VEL containing regimens | |||||||
| VEL100 + SOF | +RBV | 93.3 [82.2, 99.7] n = 39 |
100.0 [93.5, 100.0] n = 26 |
98.1 [91.9, 100.0] n = 52 |
NR | NR | 98.1 [91.9, 100.0] n = 52 |
| −RBV | 84.7 [77.8, 90.6] n = 132 |
97.6 [95.1, 99.4] n = 278 |
92.1 [86.4, 96.4] n = 124 |
97.3 [94.6, 99.2] n = 260 |
91.7 [67.6, 100.0] n = 12 |
93.9 [87.2, 98.5] n = 80 |
|
| VEL100 + SOF + VOX | +RBV | NR | NR | NR | NR | NR | NR |
| −RBV | 92.9 [83.9, 98.8] n = 55 |
100.0 [92.0, 100.0] n = 21 |
98.7 [92.7, 100.0] n = 54 |
94.4 [86.1, 99.4] n = 57 |
NR | NR | |
| SOF containing regimens | |||||||
| SOF | +RBV | 70.1 [65.9, 74.0] n = 540 |
82.8 [80.4, 85.18] n = 1039 |
77.2 [73.0, 81.2] n = 430 |
81.1 [79.0, 83.1] n = 1453 |
80.4 [75.5, 84.8] n = 283 |
58.5 [53.2, 63.6] n = 344 |
| −RBV | NR | NR | NR | NR | NR | NR | |
| Peg-IFN containing regimens | |||||||
| Peg-IFN | +RBV | 43.6 [35.1, 52.4] n = 140 |
75.4 [69.3, 81.2] n = 256 |
NR | 69.1 [67.4, 70.9] n = 2928 |
55.3 [43.0, 67.3] n = 69 |
64.0 [61.6, 66.4] n = 1752 |
| −RBV | NR | NR | NR | NR | NR | NR | |
| Peg-IFN + SOF | +RBV | 94.3 [90.0, 97.7] n = 201 |
94.0 [87.4, 98.7] n = 119 |
70.9 [63.7, 77.7] n = 170 |
99.1 [94.8, 100.0] n = 133 |
100.0 [30.3, 100.0] n = 2 |
83.3 [65.4, 96.0] n = 24 |
| −RBV | NR | NR | NR | NR | NR | NR | |
CI confidence interval, DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, I-Sq I2, LDV, ledipasvir, NR not reported, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir
aWhere SVR12 was not available, SVR24 was used
bCohorts were considered non-cirrhotic if 0% of patients were cirrhotic. Where SVR12 values of 100% are presented, this may be due to clinical trials that were exclusively HIV-positive or -negative, exclusively treatment-experienced or -naïve, or exclusively cirrhotic or non-cirrhotic